ResMed Q1 FY27 Earnings Reviewed; No Material Change to WAIT Thesis

What happened

ResMed reported its fiscal first quarter 2027 earnings, with Zacks highlighting key metrics versus Wall Street estimates and year-ago figures. The article itself provides no specific numbers, so we rely on the prior DeepValue report for context: FY26 revenue grew 10% to $5.653B with device growth of 9% and mask growth of 13%, and the market is watching whether funnel expansion converts into durable therapy revenue. The earnings release likely included updates on VirtuOx referrals, diagnostic volumes, and possibly Astral recall progress, but without concrete data, we cannot confirm whether the company beat or missed estimates. The stock closed at $221.97 on September 22, the last date in our master report, and today's article suggests a fresh earnings event that may move the stock. Our base case remains that the stock is fairly valued at $222 given incomplete conversion disclosure and Philips re-entry risk.

Implication

Longer term, the WAIT rating remains appropriate: ResMed's integrated sleep ecosystem and strong cash flow provide downside support, but the lack of disclosed PAP conversion and the potential for Philips to re-enter the U.S. market cap upside. Investors should monitor upcoming quarterly disclosures for VirtuOx referral growth and device/mask momentum; a sustained acceleration above 8% with stable margins could warrant an upgrade, while any sign of discounting or Astral cost overruns would reinforce the bear case.

Thesis delta

No thesis change from this earnings review. The article adds no new information beyond confirming that Q1 FY27 results were reported and metrics were compared to estimates. The core WAIT thesis stands: attractive entry near $205 and trim above $255, pending evidence that diagnostic funnel growth is converting into recurring PAP revenue.